6XA Stock Overview Develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. More details
Rewards Risk Analysis No risks detected for 6XA from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Olink Holding AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Olink Holding Historical stock prices Current Share Price US$24.00 52 Week High US$24.00 52 Week Low US$13.10 Beta 0.52 1 Month Change 4.35% 3 Month Change 12.15% 1 Year Change 42.01% 3 Year Change -17.81% 5 Year Change n/a Change since IPO -6.80%
Recent News & Updates
Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite Index Jul 11
Forecast breakeven date moved forward to 2024 Jul 11
Olink Holding AB (publ)(NasdaqGM:OLK) dropped from S&P Global BMI Index Jul 11 Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others. Jul 10
Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute Confidence Jun 08
Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis May 31 See more updates
Olink Holding AB (publ)(NasdaqGM:OLK) dropped from NASDAQ Composite Index Jul 11
Forecast breakeven date moved forward to 2024 Jul 11
Olink Holding AB (publ)(NasdaqGM:OLK) dropped from S&P Global BMI Index Jul 11 Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others. Jul 10
Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute Confidence Jun 08
Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis May 31
First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 loss in 1Q 2023) May 13
Forecast breakeven date pushed back to 2025 Mar 26
Full year 2023 earnings released: US$0.25 loss per share (vs US$0.11 loss in FY 2022) Mar 26
Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024 Mar 09
Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development Officer Jan 18
Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.011 loss in 3Q 2022) Nov 17
Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023 Oct 26 Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion. Oct 19
Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion. Oct 18
Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population Scale Oct 07
Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine Panel Sep 19
Forecast breakeven date moved forward to 2024 Aug 11
Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.067 loss per share (vs US$0.04 loss in 2Q 2022) Aug 10
Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023 Jul 14
Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore Ht Jul 13
Now 21% undervalued May 14
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022) May 12
Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023 May 12
Now 24% undervalued after recent price drop Mar 28
Forecast to breakeven in 2024 Feb 22
Full year 2022 earnings released: US$0.11 loss per share (vs US$0.43 loss in FY 2021) Feb 22
Now 20% undervalued Jan 21 Olink Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023
Now 22% undervalued Jan 05
Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.046 loss in 3Q 2021) Nov 16
High number of new and inexperienced directors Nov 16
Olink® Flex, A New, Unique and Fully Flexible Low-Plex Proteomics Solution Using Absolute Quantification Nov 15
Third quarter 2022 earnings released: US$0.01 loss per share (vs US$0.046 loss in 3Q 2021) Nov 11 Olink Holding AB (publ) Provides Earnings Guidance for the Full Year 2022
Olink Holding AB (Publ) Announces the Launch of Olink(R) Insight Oct 25
Olink Holding AB (publ) to Report Q3, 2022 Results on Nov 10, 2022 Oct 14
Olink Holding AB (Publ) Announces Management Appointments Sep 01
Second quarter 2022 earnings released: US$0.04 loss per share (vs US$0.089 loss in 2Q 2021) Aug 12
Olink Holding AB (Publ) Provides Revenue Guidance for the Fiscal Year 2022 Aug 12
Olink Holding AB (publ) to Report Q2, 2022 Results on Aug 11, 2022 Jul 15
Release of Olink Analyze 3.1 Streamlines Proteomic Analysis to Connect Data to Biological Insight Jun 29
First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.48 loss in 1Q 2021) May 13
Olink Holding AB (publ) Provides Revenue Guidance for the Year 2022 May 13
Forecast breakeven date moved forward to 2023 May 08
High number of new and inexperienced directors Apr 27
Olink Holding AB (publ) to Report Q1, 2022 Results on May 12, 2022 Apr 22
Forecast to breakeven in 2024 Apr 13
Olink Holding AB (publ) Announces Board Appointments Apr 08
Olink Holding AB (publ) Provides Revenue Guidance for 2022 Feb 15
Full year 2021 earnings: Revenues exceed analyst expectations Feb 15
Olink Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 Jan 12
High number of new and inexperienced directors Dec 31
Olink Holding AB (Publ) Announces Delivery of Olink® Explore 3072 Is Now Starting Dec 02
Olink Holding AB (publ) Announces Delivery of Olink® Signature Q100 Nov 24
Third quarter 2021 earnings released: US$0.046 loss per share Nov 12
Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021 Aug 12
Olink Holding AB (publ) Announces UK Biobank Pharma Proteomics Project's Expansion of Ongoing Proteomics Study Of 53,000 Participants to the New Olink Explore 3072 Platform Jul 23
Olink Holding AB (publ) has completed a Follow-on Equity Offering in the amount of $232.5 million. Jul 16
Olink Holding AB (publ) Provides Preliminary Unaudited Earnings Guidance for the Second Quarter Ended June 30, 2021 Jul 14
Olink Announces the New Explore 3072 High Throughput Proteomics Platform Jun 24
SCALLOP Launches Clinical Trial Arm to Uncover Next Level of Drug Target Insights from Proteomic Profiling Jun 16
Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2021 May 21
Olink Announces First Core Lab Running the Olink Explore Platform in Europe, Making It Available for More Researchers May 05 Shareholder Returns 6XA DE Life Sciences DE Market 7D 0.8% 4.6% 1.8% 1Y 42.0% -0.6% 12.6%
See full shareholder returns
Return vs Market: 6XA exceeded the German Market which returned 2.9% over the past year.
Price Volatility Is 6XA's price volatile compared to industry and market? 6XA volatility 6XA Average Weekly Movement 2.2% Life Sciences Industry Average Movement 7.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6XA has not had significant price volatility in the past 3 months.
Volatility Over Time: 6XA's weekly volatility has decreased from 9% to 2% over the past year.
About the Company Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company’s products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services.
Show more Olink Holding AB (publ) Fundamentals Summary How do Olink Holding's earnings and revenue compare to its market cap? 6XA fundamental statistics Market cap €3.00b Earnings (TTM ) -€31.07m Revenue (TTM ) €157.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6XA income statement (TTM ) Revenue US$170.89m Cost of Revenue US$56.60m Gross Profit US$114.29m Other Expenses US$148.00m Earnings -US$33.70m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/07/11 08:30 End of Day Share Price 2024/07/11 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Olink Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark Massaro BTIG Kyle Mikson Canaccord Genuity Matthew Sykes Goldman Sachs
Show 2 more analysts 